Skye Bioscience (SKYE) Stock News

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company focused on obesity and metabolic health disorders, has announced its participation in multiple upcoming conferences in September 2025.

The company will present at three major investment conferences: the Cantor Global Healthcare Conference (Sept. 5), the H.C. Wainwright Global Investment Conference (Sept. 8), and the Morgan Stanley Global Healthcare Conference (Sept. 10). Additionally, Skye will participate in two medical conferences: Obesity Science & Innovation in Boston and the EASD Annual Meeting in Vienna, where they will present data on nimacimab, their CB1 receptor antibody for MAFLD treatment.

Skye Bioscience (NASDAQ: SKYE) reported Q2 2025 financial results and key updates for its obesity treatment program. The company anticipates top-line data from its CBeyond™ Phase 2a study of nimacimab in late Q3/early Q4 2025, while patient enrollment has begun for the 26-week extension study. New preclinical data showed nimacimab's superior weight rebound profile compared to incretin therapy, with combination studies demonstrating enhanced weight loss of 44% when combined with tirzepatide.

Financial highlights include $48.6 million in cash as of June 30, 2025, expected to fund operations through Q1 2027. Q2 2025 saw R&D expenses of $14.3 million and a net loss of $17.6 million. The company has expanded its team to 20 employees and successfully manufactured its first batch of drug product since acquiring nimacimab.

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders, has scheduled its Q2 2025 earnings call for August 7, 2025, at 1:30 p.m. PT/4:30 p.m. ET.

The company will release its financial results and business update after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation materials through Skye's Investor Relations website. A replay will be available following the call.

Skye Bioscience (NASDAQ: SKYE) has unveiled its 'Anatomy of Progress' video series and presented preclinical data for nimacimab, its novel anti-obesity drug, at the American Diabetes Association's 85th Scientific Sessions. Nimacimab is a peripherally-restricted CB1 receptor antibody that remains over 99% excluded from the brain, potentially offering the same weight loss benefits as first-generation CB1 inhibitors without their neuropsychiatric side effects. The four-part video series details the drug's development, market positioning, and clinical progress. Preclinical data demonstrated significant weight reduction, improved metabolic homeostasis, and reduced obesity-induced inflammation in diet-induced obesity mouse models. The company also participated in an Evercore ISI panel discussing non-incretin obesity treatments, highlighting nimacimab's potential as both a standalone therapy and in combination with incretin-based drugs.

Skye Bioscience (NASDAQ: SKYE) will present new preclinical data for its CB1 inhibitor nimacimab at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago. The company will showcase its research through multiple presentations including an Evercore panel, an Innovation Hub symposium, and a poster presentation. The symposium will focus on nimacimab's mechanism of action in weight loss and metabolic regulation, highlighting its potential as a non-incretin-based therapeutic option. The poster presentation will demonstrate nimacimab's effects on metabolic homeostasis in diet-induced obesity mouse models, showing promising results in weight loss, hormonal regulation, and inflammatory biomarker reduction. The research emphasizes peripheral CB1 inhibition as a safe approach to modulate metabolic parameters.

Skye Bioscience (NASDAQ: SKYE) has partnered with Arecor Therapeutics to enhance the formulation of its obesity drug candidate nimacimab using Arecor's Arestat™ technology platform. Nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, is currently being evaluated in a Phase 2a CBeyond™ clinical trial for obesity and overweight patients, with data expected in late Q3 or early Q4 2025. The collaboration aims to develop a higher concentration formulation, with Skye funding Arecor's development activities and maintaining the option to license rights for further development and commercialization. Notably, nimacimab demonstrates a best-in-class half-life of 18-21 days, significantly longer than GLP-1-based therapies, and is being tested with once-weekly dosing. The drug shows promising advantages over existing treatments, avoiding tolerability issues of approved weight loss drugs and neuropsychiatric toxicity concerns associated with small molecule CB1 inhibitors.

Skye Bioscience (NASDAQ: SKYE), a clinical-stage biopharmaceutical company specializing in metabolic health therapeutics, has granted stock options to a new non-executive employee. The Board of Directors approved a non-qualified stock option award to purchase 100,000 shares of common stock on May 7, 2025, under the company's Amended and Restated 2024 Inducement Plan.

The stock options have an exercise price of $1.82 per share, matching Skye's closing price on Nasdaq Global Select Market. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment.

Skye Bioscience (NASDAQ: SKYE) presented a clinical pharmacokinetic and pharmacodynamic model at the European Congress on Obesity that demonstrates peripheral CB1 inhibition alone is sufficient for weight loss, while central (brain) inhibition is not required. The model analyzed data from various CB1 inhibitors including nimacimab, monlunabant, and rimonabant.

The study revealed that nimacimab showed the greatest peripheral restriction compared to small molecule-based inhibitors, with minimal brain penetration while maintaining sufficient peripheral inhibition. The Phase 2 dose of nimacimab achieves peripheral CB1 engagement at >7x the inhibition threshold while remaining >600x below this threshold in the brain, suggesting a potentially superior therapeutic index with fewer neuropsychiatric side effects.

Skye Bioscience (NASDAQ: SKYE) reported Q1 2025 results and highlighted promising developments for its obesity treatment candidate nimacimab. Key findings show that nimacimab combined with tirzepatide achieved over 30% weight loss in preclinical studies, while nimacimab alone produced 23.5% weight loss. The company's CBeyond™ Phase 2a study is progressing well, with top-line data expected in late Q3/early Q4 2025. Financially, Skye reported $59.2 million in cash and investments as of March 31, 2025, with funding through Q1 2027. Q1 2025 saw increased R&D expenses of $7.2 million (vs $1.9M in Q1 2024) and G&A expenses of $4.6 million (vs $4.2M in Q1 2024), resulting in a net loss of $11.1 million.